Table of Contents Author Guidelines Submit a Manuscript
Bioinorganic Chemistry and Applications
Volume 2012, Article ID 756374, 9 pages
http://dx.doi.org/10.1155/2012/756374
Research Article

DNA-Binding and Topoisomerase-I-Suppressing Activities of Novel Vanadium Compound Van-7

1Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yu-Shan Road, Qingdao 266003, China
2The Department of Pharmacy, Qingdao Women and Children Hospital, 127 Liao-Yang West Road, Qingdao 266034, China

Received 17 July 2012; Revised 17 August 2012; Accepted 17 August 2012

Academic Editor: Zhe-Sheng Chen

Copyright © 2012 Xiao-mei Mo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Wang, “DNA topoisomerases,” Annual Review of Biochemistry, vol. 65, pp. 635–692, 1996. View at Google Scholar · View at Scopus
  2. H. Zhang, J. C. Wang, and L. F. Liu, “Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes.,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 4, pp. 1060–1064, 1988. View at Google Scholar · View at Scopus
  3. L. Yang, M. S. Wold, and J. J. Li, “Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 4, pp. 950–954, 1987. View at Google Scholar · View at Scopus
  4. H. J. Chen and J. Hwang, “Binding of ATP to human DNA topoisomerase I resulting in an alteration of the conformation of the enzyme,” European Journal of Biochemistry, vol. 265, no. 1, pp. 367–375, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Salerno, F. Da Settimo, S. Taliani et al., “Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs,” Current Medicinal Chemistry, vol. 17, no. 35, pp. 4270–4290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. F. Riou, P. Helissey, L. Grondard, and S. Giorgi-Renault, “Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives,” Molecular Pharmacology, vol. 40, no. 5, pp. 699–706, 1991. View at Google Scholar · View at Scopus
  7. B. Poddevin, J. F. Riou, F. Lavelle, and Y. Pommier, “Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials,” Molecular Pharmacology, vol. 44, no. 4, pp. 767–774, 1993. View at Google Scholar · View at Scopus
  8. F. Leteurtre, A. Fujimori, A. Tanizawa et al., “Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions,” Journal of Biological Chemistry, vol. 269, no. 46, pp. 28702–28707, 1994. View at Google Scholar · View at Scopus
  9. B. Frydman, L. J. Marton, J. S. Sun et al., “Induction of DNA topoisomerase II-mediated DNA cleavage by β-lapacphone and related naphthoquinones,” Cancer Research, vol. 57, no. 4, pp. 620–627, 1997. View at Google Scholar · View at Scopus
  10. M. Galanski, M. A. Jakupec, and B. K. Keppler, “Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches,” Current Medicinal Chemistry, vol. 12, no. 18, pp. 2075–2094, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Galanski, “Recent developments in the field of anticancer platinum complexes.,” Recent Patents on Anti-Cancer Drug Discovery, vol. 1, no. 2, pp. 285–295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Brabec and J. Kasparkova, “Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs,” Drug Resistance Updates, vol. 8, no. 3, pp. 131–146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Ott and R. Gust, “Non platinum metal complexes as anti-cancer drugs,” Archiv der Pharmazie, vol. 340, no. 3, pp. 117–126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Evangelou, “Vanadium in cancer treatment,” Critical Reviews in Oncology/Hematology, vol. 42, no. 3, pp. 249–265, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Bishayee, A. Waghray, M. A. Patel, and M. Chatterjee, “Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence,” Cancer Letters, vol. 294, no. 1, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Y. Wu, Y. T. Li, and D. J. Xu, “Diaqua(2,2′-diamino-4,4′-bi-1,3-thiazole)oxosulfatovanadium(IV) tetrahydrate,” Acta Crystallographica Section C, vol. 61, no. 11, pp. m463–m465, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. G. W. Yang, B. H. Yuan, K. P. Ho, X. Dai, Y. C. Lin, and S. N. Zhou, “Optimization of the expression of human DNA topoisomerase I in Pichia pastoris,” Sheng wu Gong Cheng Xue Bao, vol. 20, no. 2, pp. 181–186, 2004. View at Google Scholar · View at Scopus
  18. P. De Isabella, G. Capranico, M. Binaschi, S. Tinelli, and F. Zunino, “Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells,” Molecular Pharmacology, vol. 37, no. 1, pp. 11–16, 1990. View at Google Scholar · View at Scopus
  19. D. K. Trask, J. A. DiDonato, and M. T. Muller, “Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II.,” EMBO Journal, vol. 3, no. 3, pp. 671–676, 1984. View at Google Scholar · View at Scopus
  20. J. R. Spitzner, I. K. Chung, and M. T. Muller, “Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats,” Nucleic Acids Research, vol. 18, no. 1, pp. 1–11, 1990. View at Google Scholar · View at Scopus
  21. G. Raspaglio, C. Ferlini, S. Mozzetti et al., “Thiocolchicine dimers: a novel class of topoisomerase-I inhibitors,” Biochemical Pharmacology, vol. 69, no. 1, pp. 113–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Boege, T. Straub, A. Kehr et al., “Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I,” Journal of Biological Chemistry, vol. 271, no. 4, pp. 2262–2270, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. B. C. Baguley and E. M. Falkenhaug, “The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength,” Nucleic Acids Research, vol. 5, no. 1, pp. 161–171, 1978. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Gribaldo, S. Casati, L. Figliuzzi, and E. Marafante, “In vitro myelotoxicity of environmental contaminants,” Environmental Toxicology and Pharmacology, vol. 6, no. 2, pp. 135–141, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. C. C. Kuo, J. F. Liu, and J. Y. Chang, “DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 2, pp. 946–954, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. García-Estrada, C. F. Prada, C. Fernández-Rubio, F. Rojo-Vázquez, and R. Balaña-Fouce, “DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery,” Proceedings of the Royal Society B, vol. 277, no. 1689, pp. 1777–1787, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Luo, P. Li, H. Peng, Y. Luo, and W. Tang, “Cell cycle block and apoptosis in rabbit lens epithelial cells induced by hydroxycamptothecine,” Zhonghua Yan Ke Za Zhi, vol. 38, no. 3, pp. 161–164, 2002. View at Google Scholar · View at Scopus
  28. S. Coderoni, M. Paparelli, and G. L. Gianfranceschi, “Effect of CPT on the calf thymus Topoisomerase I-mediated DNA breakage-reunion reaction: optimal conditions for the formation and reversal of the CPT trapped Topoisomerase I cleavable complex,” Molecular Biology Reports, vol. 17, no. 2, pp. 129–134, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. J. V. Tricoli, B. M. Sahai, and P. J. McCormick, “DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T1/2) cells,” Experimental Cell Research, vol. 158, no. 1, pp. 1–14, 1985. View at Google Scholar · View at Scopus
  30. N. Wu, X. W. Wu, K. Agama et al., “A novel DNA topoisomerase i inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells,” Biochemistry, vol. 49, no. 47, pp. 10131–10136, 2010. View at Publisher · View at Google Scholar · View at Scopus